Roberta Ferraldeschi
About
Roberta Ferraldeschi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Roberta Ferraldeschi has authored 62 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Roberta Ferraldeschi's work include Prostate Cancer Treatment and Research (30 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Hormonal and reproductive studies (9 papers). Roberta Ferraldeschi is often cited by papers focused on Prostate Cancer Treatment and Research (30 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Hormonal and reproductive studies (9 papers). Roberta Ferraldeschi collaborates with scholars based in United Kingdom, United States and Canada. Roberta Ferraldeschi's co-authors include Johann S. de Bono, Gerhardt Attard, David Lorente, Carmel Pezaro, Diletta Bianchini, Fiona Blackhall, Aurelius Omlin, Malcolm Ranson, Lee Lancashire and Matthew Krebs and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and Cancer Research.
In The Last Decade
Roberta Ferraldeschi
60 papers receiving 3.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Roberta Ferraldeschi United Kingdom | 28 | 1.8k | 1.5k | 1.2k | 942 | 386 | 62 | 3.3k | ||
| Marzia Del Re Italy | 34 | 1.6k 0.9× | 1.6k 1.1× | 1.3k 1.0× | 1.5k 1.6× | 394 1.0× | 167 | 3.9k | ||
| Przemyslaw Twardowski United States | 29 | 2.4k 1.3× | 2.2k 1.4× | 1.2k 1.0× | 1.6k 1.7× | 464 1.2× | 113 | 4.3k | ||
| Nina J. Karlin United States | 15 | 969 0.5× | 2.2k 1.4× | 1.1k 0.9× | 1.4k 1.5× | 555 1.4× | 47 | 4.1k | ||
| Michael L. Cher United States | 42 | 2.5k 1.4× | 2.0k 1.3× | 1.6k 1.3× | 1.9k 2.0× | 437 1.1× | 165 | 5.5k | ||
| L. Rhoda Molife United Kingdom | 25 | 1.5k 0.9× | 1.3k 0.8× | 680 0.5× | 1.3k 1.4× | 229 0.6× | 73 | 3.0k | ||
| Umberto Malapelle Italy | 43 | 2.8k 1.6× | 2.6k 1.7× | 2.4k 2.0× | 2.1k 2.2× | 364 0.9× | 265 | 5.7k | ||
| Daniel S.W. Tan Singapore | 34 | 1.9k 1.1× | 1.8k 1.2× | 965 0.8× | 1.3k 1.4× | 236 0.6× | 159 | 4.1k | ||
| Antonio Jimeno United States | 36 | 1.4k 0.8× | 3.1k 2.0× | 921 0.7× | 2.3k 2.5× | 475 1.2× | 128 | 5.2k | ||
| Ahmed O. Kaseb United States | 42 | 1.6k 0.9× | 2.9k 1.9× | 1.5k 1.2× | 1.8k 1.9× | 399 1.0× | 263 | 8.1k | ||
| Yang Lü United States | 35 | 971 0.5× | 1.9k 1.2× | 906 0.7× | 1.9k 2.1× | 723 1.9× | 171 | 4.5k |
Countries citing papers authored by Roberta Ferraldeschi
Since
Specialization
Citations
This map shows the geographic impact of Roberta Ferraldeschi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberta Ferraldeschi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberta Ferraldeschi more than expected).
Fields of papers citing papers by Roberta Ferraldeschi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Roberta Ferraldeschi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberta Ferraldeschi. The network helps show where Roberta Ferraldeschi may publish in the future.
Co-authorship network of co-authors of Roberta Ferraldeschi
This figure shows the co-authorship network connecting the top 25 collaborators of Roberta Ferraldeschi. A scholar is included among the top collaborators of Roberta Ferraldeschi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberta Ferraldeschi. Roberta Ferraldeschi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2024). CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(4_suppl). 18–18.
2.
Agarwal, Neeraj, Arun Azad, Stéphane Oudard, et al.. (2024). LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study. Annals of Oncology. 35. S1256–S1257.
3.
Kumar, Rajiv, Dionysis Papadatos-Pastos, Joaquı́n Mateo, et al.. (2020). First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 26(18). 4777–4784.
4.
Mita, Monica, Patricia LoRusso, Kyriakos P. Papadopoulos, et al.. (2020). A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma. Clinical Cancer Research. 26(12). 2819–2826.
5.
Slovin, Susan F., Syed A. Hussain, Fred Saad, et al.. (2019). Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. Clinical Cancer Research. 25(15). 4624–4633.
6.
Fazio, Carolina, Alessia Covre, Ornella Cutaia, et al.. (2018). Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy. Frontiers in Pharmacology. 9. 1443–1443.
7.
Rescigno, Pasquale, David Lorente, David Dolling, et al.. (2018). Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. European Urology Oncology. 1(1). 71–77.
8.
Lorente, David, Joaquı́n Mateo, Zafeiris Zafeiriou, et al.. (2015). Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nature Reviews Urology. 12(1). 37–47.
9.
Crespo, Mateus, Guus van Dalum, Roberta Ferraldeschi, et al.. (2015). Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. British Journal of Cancer. 112(7). 1166–1174.
10.
Ferraldeschi, Roberta, Jonathan Welti, Jun Luo, Gerhardt Attard, & Johann S. de Bono. (2014). Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 34(14). 1745–1757.
11.
Wong, Yien Ning Sophia, Roberta Ferraldeschi, Gerhardt Attard, & Johann S. de Bono. (2014). Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nature Reviews Clinical Oncology. 11(6). 365–376.
12.
Omlin, Aurelius, Carmel Pezaro, Deborah Mukherji, et al.. (2013). Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. European Urology. 64(2). 300–306.
13.
Bianchini, Diletta, Aurelius Omlin, Carmel Pezaro, et al.. (2013). First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British Journal of Cancer. 109(10). 2579–2586.
14.
Omlin, Aurelius, Carmel Pezaro, S. Zaidi, et al.. (2013). Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. British Journal of Cancer. 109(5). 1079–1084.
15.
Pezaro, Carmel, Aurelius Omlin, Amelia Altavilla, et al.. (2013). Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. European Urology. 66(3). 459–465.
16.
Ferraldeschi, Roberta, Mónica Arnedos, Kristen D. Hadfield, et al.. (2012). Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Research and Treatment. 133(3). 1191–1198.
17.
Eichholz, Andrew, Roberta Ferraldeschi, Gerhardt Attard, & Johann S. de Bono. (2011). Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Molecular and Cellular Endocrinology. 360(1-2). 68–75.
18.
Masi, Gianluca, Fotios Loupakis, Luca Emanuele Pollina, et al.. (2009). Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases. Annals of Surgery. 249(3). 420–425.
19.
Baka, Sofia, Raffaele Califano, Roberta Ferraldeschi, et al.. (2008). Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. British Journal of Cancer. 99(3). 442–447.
20.
Ferraldeschi, Roberta, Nick Thatcher, & Paul Lorigan. (2007). Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial. Expert Review of Anticancer Therapy. 7(5). 635–640.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Marzia Del Re Breakdown of academic impact, for papers by Przemyslaw Twardowski Breakdown of academic impact, for papers by Nina J. Karlin Breakdown of academic impact, for papers by Michael L. Cher Breakdown of academic impact, for papers by L. Rhoda Molife Breakdown of academic impact, for papers by Umberto Malapelle Breakdown of academic impact, for papers by Daniel S.W. Tan Breakdown of academic impact, for papers by Antonio Jimeno Breakdown of academic impact, for papers by Ahmed O. Kaseb Breakdown of academic impact, for papers by Yang Lü